GlaxoSmithKline commits to the production of one billion doses of COVID-19 vaccine adjuvant in 2021
pharmafile | May 28, 2020 | News story | Manufacturing and Production | COVID-19, GSK, coronavirus, pharma, vaccines
GlaxoSmithKline has just come forward to commit to the manufacture and distribution of one billion doses of vaccine adjuvant against COVID-19 throughout 2021.
The company made the commitment after completing a review of its global manufacturing operations, which it will be scaling up in order to meet the demands of the ongoing pandemic.
It asserted that adjuvant technology could be key in the fight against COVID-19, given its ability to provoke amplified and prolonged immune responses, as well as to lower the amount of vaccine protein needed per dose, ultimately making resources stretch further and enabling a greater number of people to be treated.
GSK said this technology would be provided to all relevant partners with suitable and promising COVID-19 vaccine candidates in development, which includes organisations in the US, Europe and China, with further collaborations expected. The company confirmed that its technology would be provided at-risk and it doesn’t expect to profit from its distribution.
“We believe that more than one vaccine will be needed to address this global pandemic and we are working with partners around the world to do so,” commented Roger Connor, President of GSK Global Vaccines. “We believe that our innovative pandemic adjuvant technology has the potential to help improve the efficacy and scale up of multiple COVID-19 vaccines. With this significant expansion in our manufacturing capacity, we can help deliver up to 1 billion doses of adjuvanted vaccines through 2021, helping protect many more people and support the global effort to fight COVID-19.”
The news follows the commitment by fellow UK firm AstraZeneca to deliver one billion doses of its own COVID-19 vaccine candidate by September this year.
Matt Fellows
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
